| dc.contributor.author | Stephen Otieno Gwer, Kennedy Odoyo Onyango | |
| dc.date.accessioned | 2020-11-20T10:46:14Z | |
| dc.date.available | 2020-11-20T10:46:14Z | |
| dc.date.issued | 2018 | |
| dc.identifier.uri | https://repository.maseno.ac.ke/handle/123456789/2889 | |
| dc.description.abstract | What is the prevalence and incidence of congenital anomalies among babies born to
women with sickle cell disease (SCD) and who have been exposed to hydroxyurea (HU) therapy at any time in their
pregnancy?
The objective of this review is to identify the proportion of babies born with congenital anomalies among babies
born to mothers with SCD who have been exposed to HU therapy at any point during pregnancy and to describe the
specific types of congenital anomalies encountered. | en_US |
| dc.subject | ickle cell disease; hydroxyurea; congenital anomalies; pregnancy JBI Database System Rev Implement Rep 2018; 16(5):1135–1140. | en_US |
| dc.title | Prevalence and incidence of congenital anomalies amongst babies born to women with sickle cell disease and exposed to hydroxyurea during pregnancy: a systematic review protocol | en_US |
| dc.type | Article | en_US |
